SRPT logo

SRPT
Sarepta Therapeutics Inc

26,747
Mkt Cap
$1.87B
Volume
8.01M
52W High
$138.81
52W Low
$10.42
PE Ratio
-6.16
SRPT Fundamentals
Price
$18.88
Prev Close
$17.82
Open
$17.52
50D MA
$20.25
Beta
1.04
Avg. Volume
5.2M
EPS (Annual)
$2.34
P/B
1.41
Rev/Employee
$1.39M
Loading...
Loading...
News
all
press releases
Sarepta Announces FDAs Approval of Updated ELEVIDYS Prescribing Information
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced an update to the prescribing information for ELEVIDYS (delandistrogene...
Business Wire·2h ago
News Placeholder
More News
News Placeholder
Connor Clark & Lunn Investment Management Ltd. Buys 370,672 Shares of Sarepta Therapeutics, Inc. $SRPT
Connor Clark & Lunn Investment Management Ltd. boosted its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 151.4% in the 2nd quarter, according to its most recent disclosure with...
MarketBeat·3d ago
News Placeholder
Fox Run Management L.L.C. Makes New $474,000 Investment in Sarepta Therapeutics, Inc. $SRPT
Fox Run Management L.L.C. acquired a new stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) during the 2nd quarter, according to its most recent disclosure with the SEC. The...
MarketBeat·3d ago
News Placeholder
Sarepta Therapeutics (NASDAQ:SRPT) Downgraded to Sell Rating by Wall Street Zen
Wall Street Zen cut Sarepta Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...
MarketBeat·5d ago
News Placeholder
Sigma Planning Corp Increases Stock Holdings in Sarepta Therapeutics, Inc. $SRPT
Sigma Planning Corp raised its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 162.8% during the second quarter, according to the company in its most recent 13F filing...
MarketBeat·5d ago
News Placeholder
C WorldWide Group Holding A S Boosts Stock Position in Sarepta Therapeutics, Inc. $SRPT
C WorldWide Group Holding A S lifted its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 95.9% during the 2nd quarter, according to its most recent filing with the Securities...
MarketBeat·7d ago
News Placeholder
Sarepta Therapeutics (NASDAQ:SRPT) Price Target Cut to $20.00 by Analysts at Barclays
Barclays reduced their price target on Sarepta Therapeutics from $22.00 to $20.00 and set an "equal weight" rating on the stock in a report on Wednesday...
MarketBeat·8d ago
News Placeholder
Sarepta Therapeutics (NASDAQ:SRPT) Given New $19.00 Price Target at Guggenheim
Guggenheim reduced their price objective on shares of Sarepta Therapeutics from $22.00 to $19.00 and set a "buy" rating on the stock in a report on Wednesday...
MarketBeat·8d ago
News Placeholder
Wells Fargo & Company Cuts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $45.00
Wells Fargo & Company reduced their price target on Sarepta Therapeutics from $50.00 to $45.00 and set an "overweight" rating on the stock in a research report on Wednesday...
MarketBeat·8d ago
News Placeholder
Sarepta Therapeutics (NASDAQ:SRPT) Trading Up 14% After Analyst Upgrade
Sarepta Therapeutics (NASDAQ:SRPT) Trading 14% Higher on Analyst Upgrade...
MarketBeat·8d ago

Latest SRPT News

View

Advertisement|Remove ads.

Advertisement|Remove ads.